Keywords
Universal influenza vaccine
Consensus sequence
Computationally-optimized broadly reactive antigen (COBRA)
How to Cite
Abstract
Each year millions of people are infected by influenza viruses, and this causes a substantial economic and health burden on our society. Influenza epidemics and pandemics are attributable to the ongoing evolution of influenza viruses through antigenic drift and shift, respectively. One of the reasons for the continuous circulation of influenza viruses in the human population is the incomplete protection conferred by currently available seasonal influenza vaccines against possible arising drifted or shifted influenza strains. Recently, tremendous efforts have been focused on the development of a more effective broadly reactive or universal influenza vaccine. The main objective of underdevelopment vaccines is to protect the human population not only from currently circulating virus strains but also from possible future variants without the need for their continuous update. Different approaches have been developed to reach this goal and elicit an effective and cross-protective immune response. Among these, consensus-based prophylactic approaches to effectively prevent influenza infections are the major focus of this review.
References
Allen J.D., Jang H., DiNapoli J., Kleanthous H. & Ross T.M. 2019. Elicitation of protective antibodies against 20 years of future H3N2 cocirculating influenza virus variants in ferrets preimmune to historical H3N2 influenza viruses. J Virol, 93 (3), e00946-18.
Allen J.D., Owino S.O., Carter D.M., Crevar C.J., Reese V.A., Fox C.B., Coler R.N., Reed S.G., Baldwin S.L. & Ross T.M. 2017. Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines. Vaccine, 35 (38), 5209-5216.
Allen J.D., Ray S. & Ross T.M. 2018. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. PLoS One, 13 (9), e0204284.
Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Diotti R.A., Saita D., Sampaolo M., Sautto G., Pianezze M. & Clementi M. 2010. Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology, 399 (1), 144-152.
Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Saita D., Diotti R.A., Sautto G., Sampaolo M. & Clementi M. 2009. Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol, 32 (4), 319-324.
Carter D.M., Darby C.A., Johnson S.K., Carlock M.A., Kirchenbaum G.A., Allen J.D., Vogel T.U., Delagrave S., DiNapoli J., Kleanthous H. & Ross T.M. 2017. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J Virol, 91 (24), e01283-17.
Carter D.M., Darby C.A., Lefoley B.C., Crevar C.J., Alefantis T., Oomen R., Anderson S.F., Strugnell T., Cortes-Garcia G., Vogel T.U., Parrington M., Kleanthous H. & Ross T.M. 2016. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol, 90 (9), 4720-4734.
Caspard H., Mallory R.M., Yu J. & Ambrose C.S. 2017. Live-attenuated influenza vaccine effectiveness in children from 2009 to 2015-2016: a systematic review and meta-analysis. Open Forum Infect Dis, 4 (3), ofx111.
Castelli M., Cappelletti F., Diotti R.A., Sautto G., Criscuolo E., Dal Peraro M. & Clementi N. 2013. Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. Clin Dev Immunol, 2013, 521231.
Crevar C.J., Carter D.M., Lee K.Y & Ross T.M. 2015. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother, 11 (3), 572-583.
Cui J., Qu N., Guo Y., Cao L., Wu S., Mei K., Sun H., Lu Y., Qin Z., Jiao P. & Liao M. 2017. Phylogeny, pathogenicity, and transmission of H5N1 avian influenza viruses in chickens. Front Cell Infect Microbiol, 7, 328.
Darricarrere N., Pougatcheva S., Duan X., Rudicell R.S., Chou T.H., DiNapoli J., Ross T.M., Alefantis T., Vogel T.U., Kleanthous H., Wei C.J. & Nabel G.J. 2018. Development of a Pan-H1 influenza vaccine. J Virol, 92 (22), e01349-18.
Elliott S.T.C., Keaton A.A., Chu J.D., Reed C.C., Garman B., Patel A., Yan J., Broderick K.E. & Weiner D.B. 2018. A synthetic micro-consensus DNA vaccine generates comprehensive influenza A H3N2 immunity and protects mice against lethal challenge by multiple H3N2 viruses. Hum Gene Ther, 29 (9), 1044-1055.
Erbelding E.J., Post D.J., Stemmy E.J., Roberts P.C., Augustine A.D., Ferguson S., Paules C.I., Graham B.S. & Fauci A.S. 2018. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis, 218 (3), 347-354.
Flannery B., Chung J.R., Belongia E.A., McLean H.Q., Gaglani M., Murthy K., Zimmerman R.K., Nowalk M.P., Jackson M.L., Jackson L.A., Monto A.S., Martin E.T., Foust A., Sessions W., Berman L., Barnes J.R., Spencer S. & Fry A.M. 2018. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep, 67 (6), 180-185.
Giles B.M., Bissel S.J., Dealmeida D.R., Wiley C.A. & Ross T.M. 2012. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol, 19 (2), 128-139.
Giles B.M., Crevar C.J., Carter D.M., Bissel S.J., Schultz-Cherry S., Wiley C.A. & Ross T.M. 2012. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis, 205 (10), 1562-1570.
Giles B.M. & Ross T.M. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine, 29 (16), 3043-3054.
Giles B.M. & Ross T.M. 2012. Computationally optimized antigens to overcome influenza viral diversity. Expert Rev Vaccines, 11 (3), 267-269.
Jhung M.A., Epperson S., Biggerstaff M., Allen D., Balish A., Barnes N., Beaudoin A., Berman L., Bidol S., Blanton L., Blythe D., Brammer L., D'Mello T., Danila R., Davis W., de Fijter S., Diorio M., Durand L.O., Emery S., Fowler B., Garten R., Grant Y., Greenbaum A., Gubareva L., Havers F., Haupt T., House J., Ibrahim S., Jiang V., Jain S., Jernigan D., Kazmierczak J., Klimov A., Lindstrom S., Longenberger A., Lucas P., Lynfield R., McMorrow M., Moll M., Morin C., Ostroff S., Page S.L., Park S.Y., Peters S., Quinn C., Reed C., Richards S., Scheftel J., Simwale O., Shu B., Soyemi K., Stauffer J., Steffens C., Su S., Torso L., Uyeki T.M., Vetter S., Villanueva J., Wong K.K., Shaw M., Bresee J.S., Cox N. & Finelli L. 2013. Outbreak of variant influenza A (H3N2) virus in the United States. Clin Infect Dis, 57 (12), 1703-1712.
Kirchenbaum G.A., Allen J.D., Layman T.S., Sautto G.A. & Ross T.M. 2017. Infection of ferrets with influenza virus elicits a light chain-biased antibody response against hemagglutinin. J Immunol, 199 (11), 3798-3807.
Laddy D.J., Yan J., Corbitt N., Kobinger G.P. & Weiner D.B. 2007. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine, 25 (16), 2984-2989.
Meyerhoff R.R., Scearce R.M., Ogburn D.F., Lockwood B., Pickeral J., Kuraoka M., Anasti K., Eudailey J., Eaton A., Cooper M., Wiehe K., Montefiori D.C., Tomaras G., Ferrari G., Alam S.M, Liao H.X., Korber B., Gao F. & Haynes B.F. 2017. HIV-1 consensus envelope-induced broadly binding antibodies. AIDS Res Hum Retroviruses, 33 (8), 859-868.
Moise L., Terry F., Ardito M., Tassone R., Latimer H., Boyle C., Martin W.D. & De Groot A.S. 2013. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother, 9 (7), 1598-1607.
Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M, Weintraub E. & Bridges C.B. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine, 25 (27), 5086-5096.
Nicholson K.G., Wood J.M. & Zambon M. 2003. Influenza. Lancet, 362 (9397), 1733-1745.
Osterholm M.T., Kelley N.S., Sommer A. & Belongia E.A. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet, Infect Dis, 12 (1), 36-44.
Palese P. 2004. Influenza: old and new threats. Nat Med, 10 (Suppl12), S82-87.Paules C. & Subbarao K. 2017. Influenza. Lancet, 390 (10095), 697-708.
Sautto G.A., Diotti R.A., Wisskirchen K. & Kahle K.M. 2017. New insights for immune-based diagnosis and therapy for infectious diseases. J Immunol Res, ID 3104719.
Sautto G.A., Kirchenbaum G.A., Diotti R.A., Criscuolo E. & Ferrara F. 2019. Next generation vaccines for infectious diseases. J Immunol Res, ID 5890962.
Sautto G.A., Kirchenbaum G.A., Ecker J.W., Bebin-Blackwell A.G., Pierce S.R. & Ross T.M. 2018. Elicitation of broadly protective antibodies following infection with influenza viruses expressing H1N1 computationally optimized broadly reactive hemagglutinin antigens. Immunohorizons, 2 (7), 226-237.
Sautto G.A., Kirchenbaum G.A. & Ross T.M. 2018. Towards a universal influenza vaccine: different approaches for one goal. Virol J, 15 (1), 17.
Scholte F.E., Tas A., Martina B.E., Cordioli P., Narayanan K., Makino S., Snijder E.J. & van Hemert M.J. 2013. Characterization of synthetic Chikungunya viruses based on the consensus sequence of recent E1-226V isolates. PLoS One, 8 (8), e71047.
Stepanova L.A., Mardanova E.S., Shuklina M.A., Blokhina E.A., Kotlyarov R.Y., Potapchuk M.V., Kovaleva A.A., Vidyaeva I.G., Korotkov A.V., Eletskaya E.I., Ravin N.V. & Tsybalova L.M. 2018. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes. J Biomed Sci, 25 (1), 33.
Tarr A.W., Backx M., Hamed M.R., Urbanowicz R.A., McClure C.P., Brown R.J.P. & Ball J.K. 2018. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Res, 160, 25-37.
Tsybalova L.M., Stepanova L.A., Shuklina M.A., Mardanova E.S., Kotlyarov R.Y., Potapchuk M.V., Petrov S.A., Blokhina E.A. & Ravin N.V. 2018. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine. PLoS One, 13 (8), e0201429.
Van Reeth K. 2018. The post-2009 influenza pandemic era: time to revisit antibody immunodominance. J Clin Invest,128 (11), 4751-4754.
Wong T.M., Allen J.D., Bebin-Blackwell A.G., Carter D.M., Alefantis T., DiNapoli J., Kleanthous H. & Ross T.M. 2017. Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J Virol, 91 (24), e01581-17.
Wu P., Lu J., Zhang X., Mei M., Feng L., Peng D., Hou J., Kang S.M., Liu X. & Tang Y. 2017. Single dose of consensus hemagglutinin-based virus-like particles vaccine protects chickens against divergent H5 subtype influenza viruses. Front Immunol, 8, 1649.
Zost S.J., Parkhouse K., Gumina M.E., Kim K., Diaz Perez S., Wilson P.C., Treanor J.J, Sant A.J., Cobey S. & Hensley S.E. 2017. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A, 114 (47), 12578-12583.